{"disease":{"id":"estrogen-receptor-positive-breast-cancer","name":"estrogen receptor positive breast cancer"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"elacestrant","indication_name":"Estrogen receptor positive advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01953588","title":"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1473,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04546009","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":992,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07340541","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02947685","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":518,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":true},{"nct_id":"NCT05306340","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":373,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT02216786","title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT04576455","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":303,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07222215","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":297,"lead_sponsor_name":"Kristina A. Fanucci","has_results":false},{"nct_id":"NCT01219699","title":"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04571437","title":"Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":204,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06062498","title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03250676","title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT07499999","title":"Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT00676663","title":"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":true},{"nct_id":"NCT06623903","title":"Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03584009","title":"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04504916","title":"A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04597580","title":"Personalised Disease Monitoring in Metastatic Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT03633331","title":"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT03886389","title":"Breast Cancer Diet Intervention Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT06439693","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03395899","title":"Pre-operative Immunotherapy Combination Strategies in Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03719495","title":"Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03285568","title":"Patterns of Prescribing and Monitoring of Palbociclib","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT02015559","title":"Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02820961","title":"Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT01743560","title":"An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02235051","title":"Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07262138","title":"Active Surveillance in Older Women With ER+ Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT02668666","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Oana Danciu, MD","has_results":true},{"nct_id":"NCT02957968","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Virginia Commonwealth University","has_results":true},{"nct_id":"NCT05076695","title":"Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":37,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06629233","title":"Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":36,"lead_sponsor_name":"University Ghent","has_results":false},{"nct_id":"NCT06525766","title":"Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03962647","title":"A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT01339442","title":"BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02988986","title":"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"The Methodist Hospital Research Institute","has_results":true},{"nct_id":"NCT02186470","title":"Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06343987","title":"The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity","phase":"NA","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT02983604","title":"GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06006910","title":"Electronic Medical Record-Based Nudge to Reduce SLNB","phase":"","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"University of Pittsburgh Medical Center","has_results":false},{"nct_id":"NCT02269670","title":"Phase II Study of Everolimus Beyond Progression","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT04965688","title":"Biology Guided Therapy for Breast Cancer for ER Positive","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Inova Health Care Services","has_results":true},{"nct_id":"NCT01394211","title":"Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT04727632","title":"[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT06613516","title":"Effect of Capivasertib on ctDNA in ER Positive Breast Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04038489","title":"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Virginia","has_results":false}],"total":48},"guidelines":[],"source":"Drug Landscape verified database"}